Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions. The COVID-19 pandemic led to skyrocketing demand for some products while simultaneously […]
The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) […]
At the 2022 Drug Information Association (DIA) annual meeting last week, it was inspiring to connect with fellow research and development (R&D) stakeholders, regulators, health […]
The MedCity INVEST PhrmaTech virtual conference, scheduled for Tuesday, July 26, offers free registration and a compelling day of conversations exploring the convergence of the […]
The model of investing huge amounts of money into one drug to try to recoup it later is problematic at best and unsustainable at worst. […]
Artificial intelligence can help drug study teams solve operational, scientific and ethical challenges. For example, AI can be used to flag real-time trends emerging in […]
Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue The recent success of the mRNA-LNP vaccines fueled biopharma to explore […]
Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben […]
Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community. Eli […]
As investment in gene therapies continues to grow rapidly, more effectively engaging patients throughout development has become a priority for any company serious about building […]
Welcome to the 3rd Annual RNAi – Based Therapeutics Summit: Overcoming Barriers for Targeted siRNA Therapeutics Built with biopharmaceutical industry insights, this in person conference will bring […]
In a competitive market, data that help companies find these critical resources can accelerate clinical trials and shorten time to market – sometimes by years.
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they […]
Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses Celebrating 20 years of […]
Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction The 2nd annual Mitochondria-Targeted Drug Development Summit returns as the only industry-led meeting focused on overcoming […]
Microsoft seeks to change the way pharma industry companies use technology to navigate human resource challenges and restore confidence in drug development supply chains.
Decipher Mechanisms of Action, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research Whilst emerging phase 3 data is set to ignite […]
Bringing in market access and collaboration earlier in the process, viewing reimbursement as the last leg of the drug developmental journey, and collaborating across key […]
The 5th Antifibrotic Drug Development Summit (AFDD) will provide you with a deeper understanding of how to progress early-stage candidates and avoid late-stage failures, know the […]
It stands to reason that policies that aim to reduce drug prices or squeeze life science companies profits are likely to decrease incentives to finance […]
Blending computational biology and AI-based methods, the goal is to identify new targets, pair these with effective chemistry, and define biomarkers to optimally position novel […]
Think of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at an early stage whether a drug was […]
Shots: Mimetas is eligible to receive up front and milestones while Roche will get an option to exclusively license specific disease models and assays for […]
We need to embrace principles from the tech industry and incorporate lessons learned from the pandemic to address the challenges of R&D productivity in pharma.
This pandemic has shown that collaboration, biosimulation and decentralized trials, and active preparedness programs lead to fast, effective drug development when we really need it. […]
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a […]
The UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts made to involve patients in the drug […]
I’ve been meaning to write some more about artificial intelligence, machine learning, and drug discovery, and this paper (open access) by Andreas Bender is an excellent […]
I’ve been meaning to write some more about artificial intelligence, machine learning, and drug discovery, and this paper (open access) by Andreas Bender is an excellent […]
Here’s a look back at the last ten years of FDA drug approvals, and it’s a pretty encouraging read. As the authors mention, in the […]
Close the Clinical Gap, Discover the Next Generation of Microbiome-based Therapeutics, and Establish New Partnerships to Accelerate Your Research The most comprehensive forum for microbiome […]
The latest funding brings total investment in the company to $750 million. The money has gone, in part, toward licensing of promising drug candidates in […]
Together, the two companies say can give drugmakers a better view at the cellular level of how a patient’s immune system is responding to a […]
I’ve had a lot of people ask me about yesterday’s protein folding news as it relates to drug discovery. And while I did a post […]
Provided by Elligo Health Research Clinical research faces a dilemma that has historically plagued the industry: the lack of diversity in research. The underrepresentation of […]
While the definition of real world evidence is still evolving, most proponents associate it with data that is derived from medical practice among heterogeneous sets […]
Shots: NVIDIA reports that it is building the “Cambridge-1” supercomputer, which will be an NVIDIA DGX SuperPOD system capable of delivering 400+ petaflops of AI […]
Let’s take a few minutes to talk about biopharma stocks in general – or to be more precise, about some of the people who invest […]
We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try […]
As everyone knows, there have been a lot of attempts to repurpose existing therapies for the coronavirus pandemic. I’ve covered several of these along the […]
Headlines appeared last night about Moderna losing a patent case that affects its coronavirus vaccine work. I know from long experience on this blog that […]
Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second […]
Roche and Blueprint Medicines Corporation, a precision therapy company headquartered in Cambridge, MA, announced on July 14, 2020 that they are entering into a licensing […]
The European Commission has approved Lynparza (olaparib) for use in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer within the European Union, it was revealed […]
SGS has announced the receipt of approval from Belgium s Federal Agency for Medicines and Health Products (FAMHP) to begin a new clinical trial of […]
GlaxoSmithKline (GSK) and Medicago have announced a collaboration for the development and evaluation of a COVID-19 vaccine candidate. The collaboration was revealed in a July […]
The European Directorate for the Quality of Medicines and Healthcare (EDQM) has announced, in a July 1, 2020 press release, the publication of a new […]
As we have discussed here previously, real-world data (RWD) and real-world evidence (RWE) offer many potential benefits in every stage of the drug discovery and […]
Copyright © 2024 | WordPress Theme by MH Themes
